Scientific posters
Date & Time: Wednesday, Sept. 30, 5:15-6:15 p.m. JST
- Poster 2.74P: BASECAMP: A Phase 2a Dose Comparison and Exploratory Efficacy Study of Forazapadin (SAT-3247) in Ambulatory Boys with Duchenne Muscular Dystrophy
Presenter: Anne M. Connolly, MD, Chief of the Division of Neurology at Nationwide Children's Hospital
- Poster 2.75P: TRAILHEAD: An Open-Label Study Evaluating Long-Term Safety and Efficacy of Forazapadin (SAT-3247) in Adults with Duchenne Muscular Dystrophy (DMD)
Presenter: Anne M. Connolly, MD, Chief of the Division of Neurology at Nationwide Children's Hospital
- Poster 2.68eP: Preclinical to human translation of regenerative index: quantification of progressive muscle degeneration and disease-modifying treatment response
Presenter: Ryan Mitchell, PhD, Satellos Senior Vice President, Head of Corporate Development
Date & Time: Friday, Oct 2, 2:15-3:15 p.m. JST
- Poster 3.31eP: Rationale and design of a safety, tolerability, and long-term efficacy study of Forazapadin (SAT-3247) in facioscapulohumeral muscular dystrophy (FSHD)
Presenter: Wildon Farwell, MD, Satellos Chief Medical Officer